Peter Connick

New approaches and procedures for cancer treatment: Current perspectives

Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study

Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis

Biological functions of mesenchymal stem cells and clinical implications

Fracture healing: mechanisms and interventions

d-Galactose-induced accelerated aging model: an overview

Stem Cell Therapies in Clinical Trials: Progress and Challenges

Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism

Mesenchymal stem cells in tumor development

Immunopathology of multiple sclerosis

Development, maintenance and disruption of the blood-brain barrier

D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices

Repair and tissue engineering techniques for articular cartilage

Adipose‐Derived Mesenchymal Stem Cells Exert Antiinflammatory Effects on Chondrocytes and Synoviocytes From Osteoarthritis Patients Through Prostaglandin E₂

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study

Therapies for multiple sclerosis: translational achievements and outstanding needs

Microenvironmental regulation of tumor progression and metastasis

The Potential of Mesenchymal Stromal Cells as a Novel Cellular Therapy for Multiple Sclerosis

Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study